Bibliometric and visualization analysis of breast cancer stem cell literature from 2011 to 2020 based on Web of Science database

doi:10.12307/2021.011

Abstract

Abstract: BACKGROUND: It has been recognized that breast cancer stem cells play an important role in the occurrence, development, metastasis, recurrence and drug resistance of breast cancer, but the action mechanism of breast cancer stem cells in it is still unclear, and the treatment of breast cancer needs further improvement.
OBJECTIVE: To explore the research status and development trend in the field of breast cancer stem cells from 2011 to 2020.
METHODS: The relevant literature data in the field of breast cancer stem cell research were obtained from the Web of Science database, and the two-dimensional bar diagram of the corresponding data was drawn by Microsoft excel 2019. The co-occurrence analysis function of VOSviewer software was used to draw the co-occurrence analysis chart of keywords and its superposition with time.
RESULTS AND CONCLUSION: (1) A total of 1 013 papers were included in this study. The number of papers, the H index, and the number of citations from the United States were the first in the world. The number of the literature on oncology is the largest. Sun Yat-Sen University is the largest producer of literature. WICHA MS is the author with the largest number of publications. National Natural Science Foundation of China supports the largest number of outputs. The largest number of publications is published in the ONCOTARGET. (2) The combination of chemotherapy and metformin and targeted antiangiogenic therapy are the key research contents in oncology. (3) In gene genetics, sox2, ezh2, and nanog are the key genes. (4) In the treatment of breast cancer stem cells, epithelial-mesenchymal transition is the main research content. (5) In molecular biology, cd24 and cd44 are the key biomarkers. (6) “Nuclear factor-κB” and “stemness” are the closest keywords to the present time. (7) Recombinant human receptor tyrosine kinase HRG/ErbB3 signals related to the nuclear factor-κB pathway, Pterostilbene and disulfiram are the research focus, and the epithelial/mesenchymal heterogeneity, miR34a-NOTCH1 axis and LINC00511/miR-185-3p/E2F1/Nanog axis related to the stemness of breast cancer stem cells are the key research contents. (8) The United States has the highest link intensity with other countries in co-country analysis. (9) It is concluded that in the field of breast cancer stem cells, the United States is the most powerful country. The research direction in this field is gradually tending to the application of breast cancer stem cells to the treatment of breast cancer. The research of nuclear factor-κB and stemness may be the current research hotspots in this field.

Key words: stem cells, breast cancer, breast cancer stem cells, nuclear factor kappa B, biomarkers, bibliometrics, visualization analysis

CLC Number:

Lu Yuyun, Huang Mei, Shi Xinlei, Chen Baoyan. Bibliometric and visualization analysis of breast cancer stem cell literature from 2011 to 2020 based on Web of Science database[J]. Chinese Journal of Tissue Engineering Research, 2021, 25(25): 4001-4008.

Figures/Tables 15

References

[1] 王宁,刘硕,杨雷,等.2018全球癌症统计报告解读[J].肿瘤综合治疗电子杂志, 2019,5(1):87-97.
[2] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132.
[3] 尤海生,高乾,陈思颖,等.乳腺癌患者治疗方案指南依从性评价[J].中国新药与临床杂志,2020,39(3):186-190.
[4] 刘婷婷,马腾,刘焱,等.乳腺癌干细胞新型多肽标志物的筛选[J].现代肿瘤医学,2020,28(11):1834-1838.
[5] 沙新海,邢广琳,黄强.补骨脂素对乳腺癌干细胞的毒性作用及TopoⅡα基因mRNA和蛋白表达水平的影响[J].临床和实验医学杂志,2019,18(22):2397-2400.
[6] 臧传鑫,刘瑞娟,赵文歌,等.乳腺癌干细胞相关信号通路及其抑制剂的研究进展[J].肿瘤学杂志,2019,25(1):27-31.
[7] 周飞,乔娜,马爽,等.乳腺癌肿瘤干细胞及表面标志物的研究进展[J].医学综述, 2019,25(20):4014-4018.
[8] 李欣怡,王皓,曾晨欣,等.乳腺癌的分子靶向药物治疗研究进展[J].肿瘤药学, 2020,10(3):257-263.
[9] 王鹏,陈晓,任浩.乳腺癌患者TGF-β、SMAD3、SOX2表达特点及临床意义[J].实验与检验医学,2020,38(1):159-161.
[10] 吴海歌,高晨慧,刘雨晴,等.乳腺癌干细胞的调控及作用[J].肿瘤防治研究, 2016,43(9):801-805.
[11] 黄天霁,杨升东,林豪,等.VOSviewer软件绘制经皮穿刺椎体成形和经皮穿刺球囊扩张椎体后凸成形领域的文献计量学科学知识图谱[J].中国组织工程研究, 2020,24(15):2410-2417.
[12] 蔡建平,江子芳.我国乳腺癌患者淋巴水肿的文献计量学分析[J].解放军护理杂志, 2018,35(15):21-24.
[13] 沙晓妍,刘竹韵,林细吟.2001-2015年Web of Science数据库中乳腺癌护理研究论文的计量学分析[J].护理学杂志,2017, 32(3):84-87.
[14] 姜桐桐,唐沛妍,史铁英.乳腺癌患者积极心理学研究领域文献可视化分析[J].医学与哲学(B),2016,37(12):80-82.
[15] HIRSCH JE. An index to quantify an individual’s scientific research output. Proc Nat Acad Sci U S A. 2005;102(46): 16569-16572.
[16] 何晓铭,龚水帝,郑小龙,等.应用文献计量学与可视化分析探讨骨与关节结核的全球研究现状及发展趋势[J].中国组织工程研究,2020,24(20):3234-3239.
[17] ILIOPOULOS D, HIRSCH HA, WANG G, et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108(4):1397-1402.
[18] CONLEY SJ, GHEORDUNESCU E, KAKARALA P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A. 2012;109(8):2784-2789.
[19] LEIS O, EGUIARA A, LOPEZ-ARRIBILLAGA E, et al. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene. 2012;31(11):1354-1365.
[20] CHANG CJ, YANG JY, XIA W, et al. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell. 2011;19(1):86-100.
[21] ZHANG C, SAMANTA D, LU H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016;113(14):E2047-E2056.
[22] LIU S, CONG Y, WANG D, et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports. 2013;2(1):78-91.
[23] RICARDO S, VIEIRA AF, GERHARD R, et al. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J Clin Pathol. 2011;64(11):937-946.
[24] PARK YH. The nuclear factor-kappa B pathway and response to treatment in breast cancer. Pharmacogenomics. 2017;18(18):1697-1709.
[25] BURNETT JP, LIM G, LI Y, et al. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells. Cancer Lett. 2017; 394:52-64.
[26] OJO D, WEI F, LIU Y, et al. Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion. Curr Med Chem. 2015;22(19): 2360-2374.
[27] LU H, CLAUSER KR, TAM WL, et al. Addendum: A breast cancer stem cell niche supported by juxtacrine signalling from monocytes Nat Cell Biol. 2015;17(12):1607.
[28] HINOHARA K, KOBAYASHI S, KANAUCHI H, et al. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci U S A. 2012;109(17):6584-6589.
[29] MAK KK, WU AT, LEE WH, et al. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-κB/microRNA 448 circuit. Mol Nutr Food Res. 2013;57(7):1123-1134.
[30] HAN D, WU G, CHANG C, et al. Disulfiram inhibits TGF-β-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK/NF-κB/Snail pathway. Oncotarget. 2015;6(38): 40907-40919.
[31] TANG T, GUO C, XIA T, et al. LncCCAT1 Promotes Breast Cancer Stem Cell Function through Activating WNT/β-catenin Signaling. Theranostics. 2019;9(24):7384-7402.
[32] ZHENG A, SONG X, ZHANG L, et al. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway. J Exp Clin Cancer Res. 2019;38(1):305.
[33] DITTMER J. Breast cancer stem cells: Features, key drivers and treatment options. Semin Cancer Biol. 2018;53:59-74.
[34] ALRAOUJI NN, AL-MOHANNA FH, GHEBEH H, et al. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol Carcinog. 2020;59(9):1041-1051.
[35] TANG W, LI M, QI X, et al. β1,4-Galactosyltransferase V Modulates Breast Cancer Stem Cells through Wnt/β-catenin Signaling Pathway. Cancer Res Treat. 2020. doi:10.4143/crt.2020.093.
[36] PEI J, WANG Y, LI Y. Identification of key genes controlling breast cancer stem cell characteristics via stemness indices analysis. J Transl Med. 2020;18(1):74.
[37] GROSSE-WILDE A, FOUQUIER D’HÉROUËL A, MCINTOSH E, et al. Stemness of the hybrid Epithelial/Mesenchymal State in Breast Cancer and Its Association with Poor Survival. PLoS One. 2015;10(5):e0126522.
[38] PARK EY, CHANG E, LEE EJ, et al. Targeting of miR34a-NOTCH1 axis reduced breast cancer stemness and chemoresistance. Cancer Res. 2014;74(24):7573-7582.
[39] LU G, LI Y, MA Y, et al. Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis. J Exp Clin Cancer Res. 2018;37(1):289.